Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract

Multi-Criteria Decision Analysis (MCDA) has been proposed as appropriate methodology for supporting many key decisions in the drug lifecycle, including regulatory authorization, health technology assessment (HTA) and prescription. The relevant decision criteria are different in these three settings: regulatory MCDAs are mostly concerned with assessing treatment benefit-risk profiles, prescription ones additionally consider convenience and patient satisfaction, and HTAs value cost and equity aspects. This presentation will question whether any single methodology can support decisions as diverse as these, but it will also argue for the value of MCDA as a general framework for structuring comparative treatment assessments. I will demonstrate the use of MCDA in benefit-risk assessment, discuss flaws present in most applications of MCDA in HTA, and argue against application of MCDA in prescription setting.

Biography

Dr. Tommi Tervonen is a Research Scientist at the Patient Preference Team of Patient-Centered Research group of Evidera, a for-profit consultancy. In his role, he serves as a principal investigator in health preference research projects. Before joining Evidera in 2015 he was an assistant professor at the Erasmus School of Economics in Rotterdam, and has held a post of visiting professor at the Systems Analysis Laboratory of Aalto University, Helsinki. He currently serves as an associate editor of Decision Support Systems. In the past, he has acted as a reviewer for the European Commission’s 2015–2019 policy impact assessment guidelines. Tommi holds a double-degree PhD (with distinction) in computer science from University of Turku (Finland) and in management science from University of Coimbra (Portugal).

Richard Doll seminars IN Public health and epidemiology

 Richard Doll

Forthcoming events

Infectious Disease Seminar Series: Evolutionary drivers of antibiotic resistance in pathogen populations

Monday, 03 October 2022, 1pm to 2pm @ BDI/OxPop Building Seminar Room LG 0-1, Old Road Campus, Headington, OX3 7LF

What is new in Polygenic Risk Scores?

Tuesday, 11 October 2022, 1pm to 2pm

Infectious Disease Seminar Series: Lessons learned - Will suffering through one pandemic help prevent another?

Monday, 17 October 2022, 1pm to 2pm @ Big Data Institute / OxPop Building, Old Road Campus, Headington, OX3 7LF

Infectious Disease Seminar Series: Global molecular epidemiology of HIV-1

Monday, 31 October 2022, 1pm to 2pm @ BDI Seminar Room LG 0-1, Old Road Campus, Headington, OX3 7LF

Infectious Disease Seminar Series: COVID-19 and Kids: what have we learnt after 3 years?

Monday, 07 November 2022, 1pm to 2pm @ BDI Seminar Room LG 1, Old Road Campus, Headington, OX3 7LF